TITLE

Quad Doesn't Disappoint: 4Q NDA Filing on Tap for Gilead

AUTHOR(S)
Powers, Marie
PUB. DATE
September 2011
SOURCE
BioWorld Today;9/21/2011, Vol. 22 Issue 183, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the second pivotal Phase III trial of the HIV Quad regimen, which includes elvitegravir, cobicistat, emtricitabin and tenofovir disoproxil fumarate, from Gilead Sciences Inc. The trial reportedly meet the expectation of Gilead Sciences and analysts by showing noninferiority at week 48 of the trial compared to ritonavir-boosted atazanavir plus Truvada. Gilead Sciences is planning to request a review for the approval of Quad by the U.S. Food and Drug Administration (FDA).
ACCESSION #
65645239

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics